BRIEF-Bristol-Myers Squibb Says Opdivo Plus Chemotherapy Significantly Improves Pathologic Complete Response In Patients With R
欧狄沃（纳武利尤单抗）联合化疗及欧狄沃联合伊匹木单抗治疗晚期不可切除或转移性食管鳞癌患者均可带来显著生存获益
Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application
Bristol-Myers' Opdivo-Chemo Combo Associated With Overall Survival Benefit In Esophageal Cancer
Bristol Myers Squibb Announces Opdivo plus Chemotherapy Demonstrated A Statistically Significant And Clinically Meaningful Benefit For The Primary And Secondary Endpoints Of Overall Survival; Co. Repo
大佬集 | 巴菲特（三）：1994年伯克希尔股东大会精选
NYSE ORDER IMBALANCE BMY.N 333313.0 ON BUY SIDE
PsiOxus Therapeutics-Bristol Myers Expand Immuno-Oncology Collaboration
PsiOxus Therapeutics Announced Updated Agreement with Bristol Myers Squibb to Advance their Clinical Stage Immuno-Oncology Collaboration
Ipsen Trades Higher After EU Approval of Kidney-Cancer Drug Combination
